Comparison of CornerLoc SI Joint Stabilization and Steroid Injections for Sacroiliac Joint Dysfunction

Sacroiliac Joint Somatic Dysfunction Clinical Trial

— COVI  

Official title:

A Prospective, Multi-Center, Bi-Phasic Randomized Design to Compare Outcomes of the CornerLoc™ SI Joint Stabilization System and Intra-Articular Sacroiliac Joint Steroid Injection in Patients With Refractory Sacroiliac Joint Dysfunction

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04218838
• Other study ID #: COVI-0001
• Status: Terminated
• Phase: N/A
• Start date: August 13, 2020
• Est. completion date: January 1, 2022

Study information

• Verified date: June 2023
• Source: CornerLoc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study has been designed to compare the safety and effectiveness of the CornerLoc™ SI Joint Stabilization System to intra-articular sacroiliac joint steroid injection in patients with refractory sacroiliac joint dysfunction.

Description:

Randomized, multicenter, open-label, randomized design to compare CornerLoc Allograft-based Sacroiliac Joint Stabilization System to Intra-articular Sacroiliac Joint Steroid Injection. Within the initial phase, referred to as the Randomized Phase, the primary determination of efficacy and safety will be 6-months following the study procedure. The analysis will be based on the randomization assignment. In the second phase of the study, referred to as the Cross-over Phase, patients who fail to respond to the randomized treatment assignment will be permitted to receive the non-randomized treatment. The basis of the sample size and hypothesis testing for this clinical investigation will be based on the Randomization Phase.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 7
• Est. completion date: January 1, 2022
• Est. primary completion date: January 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects meeting all of the following inclusion criteria by the end of the screening

phase should be considered for admission to the study:

• Subject must provide written informed consent prior to any clinical study-related procedure.
• Subject is at least 18 years (or the minimum age required by local law to consent for participation in a clinical investigation) or older at the time of enrollment.
• Subjects must meet criteria for sacroiliac joint dysfunction as determined below:
• History of persistent pain in the distribution of the sacroiliac joint despite adequate trial of physical therapy.
• NRS for pain = 7 on a 0 -.10-point scale.
• 3 of 5 provocative tests with positive findings on physical examination (SI distraction, thigh thrust, FABER, lateral compression, Gaenslen's maneuver).
• Positive response (=75% percent pain relief) to diagnostic sacroiliac joint injection on two occasions at least one week apart.
• Baseline pain with 30-day history and PROMIS-29

Exclusion Criteria:

• Patient will not be entered into the study if they meet one of the following criteria:
• Subject is unable to provide written informed consent
• Subject is enrolled, or intends to participate, in a clinical drug and/or device study (investigational device, investigational drug, new indication for a device or drug, or additional testing beyond standard of care procedures) which could confound the results of this trial as determined by the investigator.
• Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.
• Subject had prior surgical fusion implanted on same side
• Subject is pregnant or nursing
• Self-reported plan to bear children
• BMI = 40
• DEXA < -2.5 (if available)
• History of microfractures
• History of compression fractures
• History of diabetes, must have A1c <8
• History of chronic steroid use
• Chronic immunosuppression

Related Conditions & MeSH terms

• Joint Diseases
• Sacroiliac Joint Somatic Dysfunction

Intervention

Device:
• CornerLoc SI Joint Stabilization Procedure
CornerLoc minimally invasive SI Joint Stabilization System

Drug:
• Intra-articular Sacroiliac Joint Steroid Injection
Standard of Care - Steroid injection into the sacroiliac joint

Locations

Country	Name	City	State
United States	Center for Interventional Pain and Spine	Lancaster	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
CornerLoc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy of sacroiliac joint stabilization using the CornerLoc procedure in the treatment of sacroiliac joint pain by evaluating the efficacy responder rate versus an intra-articular steroid injection.	The efficacy responder rate is defined as the percentage of subjects who experience at least a 50% improvement in overall pain, as measured by the Numeric Rating Scale (NRS) for Pain, from Baseline to the 6-Month Visit. The scale is composed of 0 (no pain at all) to 10 (worst imaginable pain).	6 months
Secondary	Quality of life improvement from baseline to each follow-up visit.	PROMIS-29; Patient Reported Outcomes Measurement Information System (PROMIS) instruments contain a fixed number of items from seven PROMIS domains: depression; anxiety; physical function; pain interference; fatigue; sleep disturbance; and ability to participate in social roles and activities. The seven domains cover the most relevant areas of self-reported health for the greatest majority of people with chronic illness.; The PROMIS-29, a generic health-related quality of life survey, assesses each of the 7 PROMIS domains with 4 questions. The questions are ranked on a 5-point Likert Scale. There is also one 11-point rating scale for pain intensity.	6 months
Secondary	Clinical improvement based on pain from baseline to each follow-up visit.	Numeric Rating Scale for Pain: The Numeric Rating Scale for Pain is a measure in which individuals rate their pain on an eleven point numerical scale. The scale is composed of 0 (no pain at all) to 10 (worst imaginable pain). The patient will be asked to point to the number on the Numeric Rating Scale that best represents intensity of pain.	6 months
Secondary	Clinical improvement of low back pain from baseline to each follow-up visit.	Oswestry Disability Index (ODI): The Oswestry Disability Index (also known as the Oswestry Low Back Pain Disability Questionnaire) is a tool for evaluators used to measure a patient's permanent functional disability. Each question is scored on a scale of 0-5 with the first statement being zero and indicating the least amount of disability and the last statement is scored 5 indicating most severe disability. The scores for all questions answered are summed, then multiplied by two to obtain the index (range 0 to 100). A higher score on the ODI indicates a more severe disability caused by lower back pain.	6 months
Secondary	Clinical improvement in balance and risk for falls from baseline to each follow-up visit.	Timed Up and Go" (TUG) Test: This test measures the time for a subject to get up from a chair walk 3 meters, turn around and return to the chair and sit. Time is measured in minutes and seconds. An average of two tests is used. The shorter average time indicates clinical improvement.	6 months
Secondary	Clinical improvement from baseline to each follow-up visit.	Zurich Claudication Questionnaire (ZCQps); The Zurich Claudication Questionnaire quantifies severity of symptoms, physical function characteristics, and patient's satisfaction after treatment. The scale relates to symptoms over the past month. There are 12 questions for all patients, and a further 6 questions to measure treatment outcome. Decreasing scores indicates clinical improvement	6 months
Secondary	Clinical improvement based on use of medications from baseline to each follow-up visit.	Medication Use: All medications that are used prior to and during their participation in this study will be documented and monitored.	6 months